"instanceType","uuid:ID","id","rationale","versionIdentifier"
"StudyVersion","48fdb10b-cb54-4584-bb95-954e01fa48f0","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
